Prenetics Global 2025 Q2 Earnings Deepening Losses Amid Surging Revenue

Prenetics Global reported Q2 2025 results showing a 595% revenue increase to $17.68 million, but losses widened to $0.94 per share, reflecting ongoing financial challenges. The company raised its full-year revenue guidance to $85–$100 million.

Revenue
Prenetics Global's Q2 revenue soared to $17.68 million, a 595% increase from $2.54 million in the same period last year. This surge was driven by strong performances across its business segments: IM8 generated $9.8 million in revenue, a 70% jump from Q1; Europa reported $5.7 million; and CircleDNA contributed $2.2 million. For the first half of 2025, total revenue reached $32.3 million, reflecting a 452.1% year-over-year growth.

Earnings/Net Income
The company's losses worsened in Q2 2025, with a net loss of $-12.73 million, a 14.2% increase from $-11.15 million in Q2 2024. On a per-share basis, the loss expanded to $0.94 from $0.88. The adjusted EBITDA loss stood at $-4.1 million for the quarter. Despite the revenue surge, the company remains unprofitable, having posted losses in four consecutive Q2s.

Price Action
Prenetics Global’s stock price showed positive momentum in the latest trading period, rising 0.85% on the day, surging 24.54% for the week, and climbing 30.00% month-to-date.

Post-Earnings Price Action Review
Danny Yeung, CEO and Co-Founder of Prenetics, highlighted the company's strategic execution, particularly the impressive growth of IM8, which generated $5.9 million in monthly revenue in August 2025 with a CAGR of over 3,100%. He emphasized the brand's 8 million servings delivered and 300,000 customer orders, underscoring its impact on health and wellness. Yeung also outlined Prenetics' Bitcoin treasury strategy as a disciplined approach to value preservation and long-term shareholder value. He expressed confidence in the company's path to profitability in early 2026, supported by a strong balance sheet of $90 million in cash and BTC.

Guidance
Prenetics Global increased its FY2025 revenue guidance to $85–$100 million, with segment-specific projections of $55–$60 million for IM8, $20–$25 million for Europa, and $10–$15 million for CircleDNA. The company expects to achieve break-even by Q1 2026 and transition to EBITDA positivity thereafter.

Additional News
Prenetics announced the sale of ACT Genomics to Delta Electronics, Inc., with a gross proceeds of $46.3 million, expected to close in Q4 2025. The company also expanded its Bitcoin treasury, accumulating 228 Bitcoin as of September 10, 2025, with a plan to add 1 BTC daily. Additionally, Prenetics raised its FY2025 revenue guidance amid strong performances from its health and wellness segments, particularly IM8.